US Edition
News from targetedonc.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top targetedonc.com News
United States · United Statesfizkes // Shutterstock Men’s mental health is often overlooked, but it shouldn’t be. Talking about emotions isn’t always easy — especially for men. Society often teaches men to “tough it out” instead of seeking help. This mindset can take a serious toll. Every year, six million men in the U.S. experience depression, and men are two to three times more likely to deal with unhealthy substance use than women. Yet men are far less likely to seek t…See the Story
Redefining the conversation around men’s mental health | News Channel 3-12
66% Center coverage: 6 sources
United States · United States(MedPage Today) -- The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated...See the Story
Two Drugs Approved for NPM1-Mutated Leukemia
80% Center coverage: 5 sources
Cancer · United States(MedPage Today) -- The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer.
FDA granted the targeted agent an...See the Story
Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar
100% Center coverage: 1 sources
